IL175032A0 - Inhalable pharmaceutical formulations employing lactose anhydrate nad methods of administering the same - Google Patents

Inhalable pharmaceutical formulations employing lactose anhydrate nad methods of administering the same

Info

Publication number
IL175032A0
IL175032A0 IL175032A IL17503206A IL175032A0 IL 175032 A0 IL175032 A0 IL 175032A0 IL 175032 A IL175032 A IL 175032A IL 17503206 A IL17503206 A IL 17503206A IL 175032 A0 IL175032 A0 IL 175032A0
Authority
IL
Israel
Prior art keywords
nad
administering
methods
same
pharmaceutical formulations
Prior art date
Application number
IL175032A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL175032A0 publication Critical patent/IL175032A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL175032A 2003-10-28 2006-04-20 Inhalable pharmaceutical formulations employing lactose anhydrate nad methods of administering the same IL175032A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51507703P 2003-10-28 2003-10-28
PCT/US2004/035129 WO2005044187A2 (en) 2003-10-28 2004-10-22 Inhalable pharmaceutical formulations employing lactose anhydrate and methods of administering the same

Publications (1)

Publication Number Publication Date
IL175032A0 true IL175032A0 (en) 2008-04-13

Family

ID=34572801

Family Applications (1)

Application Number Title Priority Date Filing Date
IL175032A IL175032A0 (en) 2003-10-28 2006-04-20 Inhalable pharmaceutical formulations employing lactose anhydrate nad methods of administering the same

Country Status (6)

Country Link
US (1) US20070053843A1 (enExample)
EP (1) EP1686960A4 (enExample)
JP (1) JP2007509941A (enExample)
CA (1) CA2543482A1 (enExample)
IL (1) IL175032A0 (enExample)
WO (1) WO2005044187A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
GB0520794D0 (en) * 2005-10-12 2005-11-23 Innovata Biomed Ltd Inhaler
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
TR200909788A2 (tr) * 2009-12-25 2011-07-21 Bi̇lgi̇ç Mahmut Tiotropyum içeren inhalasyona uygun kuru toz formülasyonu
US8834931B2 (en) 2009-12-25 2014-09-16 Mahmut Bilgic Dry powder formulation containing tiotropium for inhalation
TR201000685A2 (tr) * 2010-01-29 2011-08-22 Bi̇lgi̇ç Mahmut Salmeterol ve flutikazon içeren farmasötik preparatlar.
EP2533765A2 (en) * 2010-01-29 2012-12-19 Mahmut Bilgic Pharmaceutical compositions comprising formoterol and mometasone
WO2014007771A2 (en) 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
US20150165037A1 (en) * 2012-07-05 2015-06-18 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising corticosteroid and sorbitol
MX2015015132A (es) * 2013-04-29 2016-02-18 Sanofi Sa Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen.
JP6480866B2 (ja) 2013-09-30 2019-03-13 第一三共株式会社 スプレードライ法を用いたＤ−マンニトールα型結晶の選択的製造方法
CN106102737B (zh) * 2013-10-22 2019-06-14 综合医院公司 色甘酸衍生物以及成像和治疗的相关方法
WO2016037166A1 (en) * 2014-09-07 2016-03-10 Yu Zhang Novel anti-oxidant compositions and methods of delivery
MX392636B (es) 2014-10-31 2025-03-24 Glaxosmithkline Ip Dev Ltd Formulacion en polvo.
CN116889562A (zh) 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
MX2021006869A (es) 2018-12-10 2021-07-02 Massachusetts Gen Hospital Esteres de cromolin y usos de los mismos.
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
FI88112C (fi) * 1985-07-30 1993-04-13 Glaxo Group Ltd Anordning foer administrering av laekemedel till patienter
SK280967B6 (sk) * 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6536427B2 (en) * 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
PE44995A1 (es) * 1994-01-27 1995-12-18 Schering Corp Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
GB9404945D0 (en) * 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
TR199701167T1 (xx) * 1995-04-14 1998-03-21 Glaxo Wellcome Inc. Albuterol i�in �l��lm�� doz inhaleri.
AP979A (en) * 1995-04-14 2001-06-28 Glaxo Wellcome Inc Metered dose imhaler for salmeterol.
SK139197A3 (en) * 1995-04-14 1998-04-08 Glaxo Wellcome Inc Metered dose inhaler for beclomethasone dipropionate
EE04004B1 (et) * 1995-04-14 2003-04-15 Glaxo Wellcome Inc. Flutikasoonpropionaati doseeriv inhalaator
US6258341B1 (en) * 1995-04-14 2001-07-10 Inhale Therapeutic Systems, Inc. Stable glassy state powder formulations
GB9606188D0 (en) * 1996-03-23 1996-05-29 Danbiosyst Uk Pollysaccharide microspheres for the pulmonary delivery of drugs
GB9626960D0 (en) * 1996-12-27 1997-02-12 Glaxo Group Ltd Valve for aerosol container
GB9700226D0 (en) * 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US6495167B2 (en) * 1997-03-20 2002-12-17 Schering Corporation Preparation of powder agglomerates
PL192441B1 (pl) * 1997-03-20 2006-10-31 Schering Corp Sposób wytwarzania aglomeratów i postać dawkowania środka farmakologicznie aktywnego
EP0876814A1 (en) * 1997-05-07 1998-11-11 "PHARLYSE", Société Anonyme Dry powder inhaler excipient, process for its preparation and pharmaceutical compositions containing it
TW533865U (en) * 1997-06-10 2003-05-21 Glaxo Group Ltd Dispenser for dispensing medicament and actuation indicating device
GB2329939A (en) * 1997-06-26 1999-04-07 Glaxo Group Ltd Self-lubricating valve stem for aerosol containers
ATE382386T1 (de) * 1998-11-13 2008-01-15 Jagotec Ag Multidosis-trockenpulverinhalator mit pulverreservoir
US6390291B1 (en) * 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
MXPA03007908A (es) * 2000-02-17 2004-12-06 Teva Pharma Una formulacion farmaceutica estable que comprende una modificacion de torsemida ii.

Also Published As

Publication number Publication date
CA2543482A1 (en) 2005-05-19
US20070053843A1 (en) 2007-03-08
EP1686960A2 (en) 2006-08-09
WO2005044187A3 (en) 2006-03-23
WO2005044187A2 (en) 2005-05-19
EP1686960A4 (en) 2007-03-07
JP2007509941A (ja) 2007-04-19

Similar Documents

Publication Publication Date Title
IL175032A0 (en) Inhalable pharmaceutical formulations employing lactose anhydrate nad methods of administering the same
AU156078S (en) Set of cannula heads
EP1487411A4 (en) THERAPEUTIC FORMULATIONS SUPPORTED BREATHABLE
IL165860A0 (en) Administration of therapeutic viruses
AU2003261251A1 (en) Methods of delivering therapeutic agents
AU2003296897A8 (en) Pharmaceutical formulations of camptothecine derivatives
AU2003215334A1 (en) Inhalable formulations for sustained release
AU2003220348A1 (en) Ct integrated respiratory monitor
IL169338A0 (en) Therapeutic formulations for the treatment of beta-amyloid related diseases
IL183587A0 (en) Methods of using [3.2.0] heterocyclic compounds and analogs thereof
IL219397A0 (en) Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
EP1551426A4 (en) PROCESS FOR THE ADMINISTRATION OF FGF18
EP1965823A4 (en) METHOD FOR THE ADMINISTRATION OF HYPOGLYKEMIC AGENTS
AU2003286741A1 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
AU2002362774A1 (en) Cyclosporin analogs for the treatment of lung diseases
PL372773A1 (en) Oral administration of epothilones
EP1551425A4 (en) THERAPEUTIC FORMULATIONS
EP1534295A4 (en) FORMULATIONS AND METHODS OF ADMINISTRATION OF CEPHALOTAXINS, INCLUDING HOMOHARRINGTONIN
ZA200707934B (en) Thereapeutic formulations for the treatment of beta-amyloid related diseases
IL175014A0 (en) Method of administering therapeutic injections
GB0202900D0 (en) Novel formulations of drugs
IL166337A0 (en) Oral administration of calctionin
IL176404A (en) Pharmaceutical composition of vinflunine which is intended for parenteral administration, preparation method thereof and use of same
PT1648440E (pt) Formulações semi-sólidas para a administração oral de taxóides
ZA200506750B (en) Pharmaceutical composition comprising 5-methyl-2-2'-(chloro-6'-fluroanilino) phenylacetic acid